NCT03657420View on ClinicalTrials.gov

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 30, 2019

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

ABI-009

ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.

DRUG

Pomalidomide

Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.

DRUG

Dexamethasone

Dexamethasone is a steroid which is believed to kill cancer cells

Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

Sponsors

Collaborators (1)

Aadi Bioscience, Inc.
All Listed Sponsors
collaborator

Aadi Bioscience, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT03657420 - Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter